Molecular Weight (MW)

387.39

Formula

C17H21N7O4

CAS No.

326914-06-1

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 33 mg/mL (85.2 mM)

Water: <1 mg/mL

Ethanol: <1 mg/mL

Other info

Chemical Name: 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine

InChi Key: MSSXBKQZZINCRI-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H21N7O4/c25-24(26)14-3-1-13(2-4-14)18-15-19-16(22-5-9-27-10-6-22)21-17(20-15)23-7-11-28-12-8-23/h1-4H,5-12H2,(H,18,19,20,21)

SMILES Code: O=[N+](C1=CC=C(NC2=NC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=C1)[O-]

Synonyms

In Vitro

In Vitro activity: MHY1485 suppresses the basal autophagic flux. MHY1485 causes the accumulation of LC3II and enlargement of the autophagosomes in a dose- and time- dependent manner. MHY1485 increases phospho-mTOR levels and phosphorylation of downstream S6K1 and rpS6 proteins without affecting total mTOR content, total S6K1 and rpS6 levels. Short-term treatment of ovaries with MHY1485 followed by allo-transplantation promoted secondary follicle growth. Treatment with MHY1485 and subsequent grafting allowed the derivation of mature oocytes and healthy offspring.

Cell Assay: MHY1485 (10 μM; 4 hours) shows that GCDC-induced autophagic activity is s inhibited by upregulating p-mTOR expression and downregulating LC3 and p62 expression in HCC cells. MHY1485 (5 μM; 6 hours) increases the LC3II/LC3I ratio in a dose and time-dependently manner due to presumably inhibited LC3II degradation in rat liver Ac2F cells. MHY1485 (0.5-2 μM; 6 hours) increases the phosphorylation of mTOR at ser2448 and upregulates the level of phosphorylation of 4E-BP1 in a dose-dependently manner in Ac2F cells.

In Vivo

Animal model

Formulation & Dosage

References

PLoS One. 2012;7(8):e43418; PLoS One. 2015; 10(2): e0117769.